This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

XenoPort Awarded Grant From The Michael J. Fox Foundation To Examine XP23829 In Preclinical Models Of Parkinson’s Disease

Stocks in this article: XNPT

XenoPort, Inc. (Nasdaq:XNPT) announced today that it has been awarded a grant from The Michael J. Fox Foundation (MJFF) for Parkinson’s Research to support preclinical studies to explore XP23829 for its ability to protect against neurodegeneration in experimental preclinical models of Parkinson’s disease. The grant of $347,075 was awarded under the Foundation's Therapeutics Development Initiative Program aimed at supporting preclinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and improving treatment of symptoms.

“Evaluating drugs that could potentially slow the progression of Parkinson’s disease is a high-priority research area for The Michael J. Fox Foundation,” said Kuldip Dave, PhD, associate director of research programs at MJFF. “We are encouraged by research that suggests that fumaric acid esters could slow the progression of the neurodegenerative process. We are hopeful that XenoPort’s efforts to this end could help to speed progress toward a breakthrough treatment for patients with Parkinson’s disease.”

XenoPort is evaluating XP23829, a fumaric acid ester compound and a prodrug of monomethyl fumarate (MMF). Fumaric acid ester compounds have shown immuno-modulatory and neuroprotective effects in cell-based systems and preclinical models of disease. Dimethyl fumarate (DMF), also a fumaric acid ester compound and a prodrug of MMF, has been shown to be effective in clinical trials in patients with relapsing-remitting multiple sclerosis (RRMS) and psoriasis. A potential shortcoming of DMF-based therapy is that patients can suffer from gastrointestinal adverse events.

The biological mechanisms underlying the beneficial effects of fumaric acid ester prodrugs may be due to Nrf2 activation by MMF. Nrf2 activation is thought to combat oxidative neurodegeneration by increasing the genetic expression of a number of antioxidant enzymes and downregulating, or reducing, production of proinflammatory molecules. In human genetic studies, patients with genetic sequences associated with high Nrf2 transcriptional activity also showed decreased risk of developing Parkinson’s disease or an increased age of onset of the disease. In preclinical models of Parkinson’s disease, MPTP-induced neurotoxicity of dopaminergic neurons was reduced by activation of Nrf2 either through addition of Nrf2-inducing compounds or by over expression of Nrf2.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs